Sugi Predict

Sugi Predict / Compounds / SCHEMBL363197

SCHEMBL363197

SCHEMBL363197

CCCCCCCCCCCCCCCCCC(=O)OC(=O)/C=C/C(=O)OC(=O)CCCCCCCCCCCCCCCCC.[NaH].[NaH]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGKA P23743 1/20 0.53
▸ TSHR P16473 3/20 0.50
▸ LMNA P02545 2/20 0.50
▸ POLB P06746 1/20 0.49
▸ POLA1 P09884 1/20 0.49
▸ PAM P19021 2/20 0.48
▸ MAPT P10636 2/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ CES2 O00748 3/20 0.46
▸ CES1 P23141 3/20 0.46
▸ HCAR2 Q8TDS4 1/20 0.46
▸ ATM Q13315 1/20 0.45
▸ PPARG P37231 3/20 0.45
▸ PPARD Q03181 3/20 0.45
▸ PPARA Q07869 3/20 0.45
▸ GPR84 Q9NQS5 2/20 0.45
▸ HDAC11 Q96DB2 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ SLC22A6 Q4U2R8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15152879 1.00 DGKA (0.53) DGKATSHRLMNAPOLBPOLA1
SCHEMBL28554767 0.98 DGKA (0.55) DGKATSHRLMNAPOLBPOLA1
SCHEMBL5308542 0.98 DGKA (0.55) DGKATSHRLMNAPOLBPOLA1
SCHEMBL28575547 0.98 DGKA (0.55) DGKATSHRLMNAPOLBPOLA1
SCHEMBL5954675 0.98 DGKA (0.55) DGKATSHRLMNAPOLBPOLA1
SCHEMBL668233 0.98 DGKA (0.55) DGKATSHRLMNAPOLBPOLA1
SCHEMBL1304410 0.98 DGKA (0.55) DGKATSHRLMNAPOLBPOLA1
SCHEMBL5954671 0.98 DGKA (0.55) DGKATSHRLMNAPOLBPOLA1
SCHEMBL1304408 0.98 DGKA (0.55) DGKATSHRLMNAPOLBPOLA1
SCHEMBL28060923 0.98 DGKA (0.55) DGKATSHRLMNAPOLBPOLA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 870 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026103205-A1 ORALLY DISINTEGRATING TABLET OF PIMAVANSERIN OR SALT THEREOF AND PREPARATION METHOD THEREFOR 江苏百奥信康医药科技有限公司 2026-05-21 — — WO claimed
CN-122057043-A Cilostazol controlled-release preparation and preparation method thereof 石家庄科仁医药科技有限公司 2026-05-19 — — CN claimed
WO-2026098600-A1 FORMULATION CONTAINING HETEROCYCLIC COMPOUND OR COMPLEX FORMED FROM HETEROCYCLIC COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALT, PREPARATION METHOD THEREFOR, AND USE THEREOF 湖北生物医药产业技术研究院有限公司 2026-05-15 — — WO claimed
WO-2026097873-A1 HALOGENATED INDOLINONE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF, HALOGENATED INDOLINONE DERIVATIVE AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 广州湾区生物医药研究院 2026-05-15 — — WO claimed
US-20260014155-A1 TICAGRELOR SOLID DISPERSION, METHOD FOR PREPARING SAME, AND USE THEREOF WISDOM PHARMACEUTICAL CO LTD (CN) 2026-01-15 — — US claimed
US-20250281390-A1 OSMOTIC PUMP TABLET, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI WD PHARMACEUTICAL CO., LTD (CN) 2025-09-11 — — US claimed
CN-116157391-B Pharmaceutical composition comprising EGFR inhibitor and preparation method thereof 上海海雁医药科技有限公司 2025-06-24 — — CN claimed
CN-120131580-A Toluene sulfonic acid Lu Meipai long capsule and preparation method and application thereof 四川奥邦古得药业有限公司 2025-06-13 — — CN claimed
CN-120053385-A Ondansetron hydrochloride tablet and preparation method thereof 福安药业集团宁波天衡制药有限公司 2025-05-30 — — CN claimed
CN-118986905-B Apatinib mesylate tablet and preparation method thereof 郑州大学第一附属医院 2025-04-29 — — CN claimed
CN-111803451-A pH-responsive oral veterinary drug granules for treating ruminant infection and preparation method thereof 宁波西敦医药包衣科技有限公司 2020-10-23 — — CN claimed
WO-2020135491-A1 PROPAFENONE MICROTABLET, MULTIPLE-UNIT DOSAGE FORM COMPRISING PROPAFENONE MICROTABLET, AND PREPARATION METHODS THEREFOR AND USES THEREOF 上海宣泰医药科技有限公司 2020-07-02 — — WO claimed
WO-2020135401-A1 TREATMENT USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND 正大天晴药业集团股份有限公司 2020-07-02 — — WO claimed
CN-111297823-A Preparation method of oseltamivir phosphate capsule 石药集团中奇制药技术（石家庄）有限公司 2020-06-19 — — CN claimed
CN-110974845-A Pharmaceutical composition for improving gastrointestinal health, preparation method thereof and preparation method of pharmaceutical preparation 苏州华健瑞达医药技术有限公司 2020-04-10 — — CN claimed
CN-110934848-A Telmisartan capsule and preparation method thereof 江西杏林白马药业有限公司 2020-03-31 — — CN claimed
CN-105999159-B Brown sugar and saussurea involucrata composition and preparation method thereof 深圳太太药业有限公司 2020-03-24 — — CN claimed
US-9763885-B2 Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases ALTHERA LABORATORIES LTD. (IE) 2017-09-19 — — US claimed
US-20060252049-A1 Growth-promoting and immunizing subcutaneous implant IVY ANIMAL HEALTH, INC. 2006-11-09 — — US claimed
US-5955105-A THYROXINE, WATER SOLUBLE GLUCOSE POLYMER, AND INSOLUBLE CELLULOSE POLYMER; SHELF LIFE KNOLL PHARMACEUTICAL COMPANY (US) 1999-09-21 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014155-A1 TICAGRELOR SOLID DISPERSION, METHOD FOR PREPARING SAME, AND USE THEREOF ABCB11, PF4, ABCB1 DGKA 1531/4885TSHR 2519/4885LMNA 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.